Chinese Tech Stocks Rally on Easing Geopolitical Tensions

Sudden De-escalation of Geopolitical Risks: The Asset Reallocation Logic Behind the Strong Rebound in U.S.-Listed Chinese Stocks

Global financial markets recently experienced a rare “shift in risk appetite.” Catalyzed by an unexpected de-escalation in U.S.–Iran tensions, U.S.-listed Chinese stocks and A-shares traded overnight both surged—breaking a multi-week pattern of weakness and reflecting international capital’s renewed assessment of the relative value of Chinese assets. On April 17, the Nasdaq Golden Dragon China Index rose over 1.3% in a single day; major platform companies—including Alibaba, Pinduoduo, Baidu, and Tencent—all posted gains. Biotech firm Zai Lab surged 3.7%; autonomous driving pioneer Pony.ai jumped 6.8%; and Kingsoft Cloud rose 3.6%, buoyed by strengthened market logic around AI infrastructure. Concurrently, the FTSE China A50 futures contract gained 0.6% overnight, while the Emerging Markets Foreign Exchange Index halted its prior consecutive decline. This broad-based rally is no isolated event—it reflects a structural reallocation of capital, driven by the marginal retreat of geopolitical risk, improved global liquidity expectations, and reinforcing policy support signals from China.

“Unblocking” the Strait of Hormuz: The Pivotal Turning Point for Rapid Unwinding of Geopolitical Risk Premium

The immediate catalyst for this rally was the unexpectedly rapid easing of U.S.–Iran relations. On April 17, former U.S. President Donald Trump released a series of critical statements on social media:

• Iran, with U.S. assistance, has either cleared or is actively clearing all naval mines from the Strait of Hormuz;
• Tehran has formally pledged not to block the Strait of Hormuz, declaring that the waterway “will no longer be used as a weapon against the world”;
• The U.S. confirmed Iran’s agreement to halt uranium enrichment activities—“Iran has agreed to everything.”

Notably, Trump also explicitly stated that “the U.S. has prohibited Israel from bombing Lebanon” and emphasized Washington’s intention to “address Hezbollah issues with Lebanon alone.” While these declarations fall short of formal treaties, they have substantively dismantled the market’s most pessimistic scenario—that regional conflict would escalate into full-scale war across the Middle East.

The market impact was immediate and unambiguous: WTI crude oil plunged 14.5% to $80.87 per barrel; Brent crude tumbled 13% to $86.09; European natural gas prices dropped sharply—by up to 10%—and diesel futures collapsed 15%. This steep energy-price correction signals a marked reduction in global inflationary pressure and supply-chain disruption risks. According to Axios, citing U.S. officials, substantive progress has been made in negotiations on a three-page Memorandum of Understanding (MOU) between the U.S. and Iran to end hostilities. In other words, the geopolitical risk premium that had accumulated over months is now being unwound at an exceptionally rapid pace—and Chinese assets, precisely due to their low correlation with Middle Eastern geopolitical developments, have naturally emerged as a “safe-haven alternative” for global capital.

Low Correlation + Policy Backstop: Dual Drivers Amplifying China’s Asset Re-allocation Appeal

The strength shown by U.S.-listed Chinese stocks and A-shares overnight stems not merely from declining external risks—but more fundamentally from their intrinsic attributes and supportive domestic policy environment, which together generate a “certainty premium.”

First, China’s capital markets bear no direct transmission channel to Middle Eastern geopolitical conflicts; their volatility has long remained below the emerging-market average. When global risk assets—such as U.S. tech stocks—come under pressure amid war-related anxiety, U.S.-listed Chinese stocks exhibit comparatively higher elasticity, thanks to historically depressed valuations and clear earnings recovery expectations. Data show the Nasdaq Golden Dragon China Index currently trades at a trailing-twelve-month (TTM) P/E ratio of just 12.3x—nearly 60% below its 2021 peak—indicating a significantly enhanced margin of safety.

Second, domestic policy support signals continue to strengthen. Although no large-scale stimulus package has been announced, the pace of capital-market reform has clearly accelerated:

• The China Securities Regulatory Commission (CSRC) recently affirmed its support for technology firms seeking listings on mainland exchanges and introduced a “green channel” for IPO reviews in sectors including biopharmaceuticals and artificial intelligence;
• Local governments across multiple provinces are expediting approvals for road-testing licenses for intelligent connected vehicles and piloting cross-border data flows—paving the way for commercialization by autonomous driving firms like Pony.ai;
• The Ministry of Industry and Information Technology (MIIT) is spearheading formulation of the Three-Year Action Plan for AI Infrastructure Development, directly benefiting IDC service providers such as Kingsoft Cloud.

This “precision-drip” style of policy support, when combined with improving overseas liquidity conditions, creates powerful synergies: easing inflation pressures have revived expectations of Federal Reserve rate cuts, pushing down U.S. Treasury yields and supporting valuation recoveries across global growth equities. High-beta U.S.-listed Chinese tech stocks thus emerge as the natural first choice for liquidity reallocation.

Tech & Pharma Lead the Rally: Dual Resonance of Industrial Fundamentals and Capital-Cycle Dynamics

At the sector level, this rebound exhibits two distinct, parallel themes: “hard tech” and “hard demand.” The surge in autonomous driving and AI infrastructure validates a positive feedback loop forming between industrial capital and secondary markets: Pony.ai recently secured new fully unmanned commercial operation licenses in Guangzhou and Beijing, with order volume rising over 40% quarter-on-quarter; Kingsoft Cloud announced a joint launch—with NVIDIA—of an integrated “cloud-AI computing appliance” tailored for large-model training, slashing customer contracting cycles to under two weeks. These developments reflect tangible progress—not speculative hype—in technology deployment and commercial monetization.

Meanwhile, the pharmaceutical sector embodies dual resilience: “rigid demand” plus “policy breakthroughs.” Zai Lab’s share price rose 3.7%, driven by FDA Breakthrough Therapy designation for its ovarian cancer drug ZL-2307 and accelerated progress in domestic reimbursement negotiations. Against the backdrop of routine centralized drug procurement (CDP), innovative biopharma firms are reshaping their valuation anchors through a “dual-reporting, dual-approval, dual-market” strategy—leveraging robust U.S. clinical trial data as key leverage in domestic pricing talks, while domestic reimbursement-driven volume growth feeds back into R&D investment. This self-reinforcing “innovation-for-space, globalization-for-depth” model markedly improves the sector’s risk-adjusted returns.

Marginal Liquidity Improvement: Valuation-Repair Window Opens for High-Beta Assets

A word of caution: this rally remains fundamentally liquidity-driven valuation repair—not a broad-based, earnings-driven reversal. The Q1 2024 earnings season for U.S.-listed Chinese stocks has yet to begin, and most firms’ earnings inflection points still await confirmation from Q2 data. Nevertheless, it is undeniable that marginal improvement in overseas liquidity has opened a valuation-repair window for high-beta assets: a drop in the 10-year U.S. Treasury yield from 4.3% to below 4.0% could lift the forward P/E embedded in the Nasdaq Golden Dragon Index by 15–20%. Under these conditions, capital naturally gravitates toward subsectors offering the greatest elasticity, clearest policy backing, and most visible industrial progress—precisely why autonomous driving, AI compute, and innovative pharmaceuticals are leading the charge.

In the near term, if the U.S.–Iran MOU is formally signed, the geopolitical risk premium may compress further, strengthening the relative appeal of RMB-denominated assets. Over the medium term, however, investors must closely monitor the pace of domestic economic data recovery and the tangible implementation outcomes of capital-market reforms. Should policy backstops and industrial breakthroughs converge, the current rebound in U.S.-listed Chinese stocks and A-shares may evolve from a “tactical trading opportunity” into a “strategic allocation.”